SILO PHARMA, INC. Deferred Tax Assets, Operating Loss Carryforwards
SILO PHARMA, INC. (SILO) had Deferred Tax Assets, Operating Loss Carryforwards of $4.38 million as of 2025-12-31, per its POS AM filed 2026-04-14.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-04-14
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $4.38M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $2.96M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $2.36M; Deferred Tax Assets, Operating Loss Carryforwards as first filed $2.54M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $1.55M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $4.38M POS AM · filed 2026-04-14 | |
| 2024-12-31 | $2.96M POS AM · filed 2026-04-14 | |
| 2023-12-31 | $2.36M 10-K · filed 2025-03-28 | $2.54M 10-K · filed 2024-03-25 |
| 2022-12-31 | $1.55M 10-K · filed 2024-03-25 | |
| 2021-12-31 | $609.53K 10-K · filed 2023-03-24 | $1.65M 10-K · filed 2022-03-28 |
| 2020-12-31 | $868.34K 10-K · filed 2022-03-28 | |
| 2019-12-31 | $490.82K 10-K/A · filed 2021-05-17 | |
| 2018-12-31 | $291.61K 10-K · filed 2020-03-20 | |
| 2017-12-31 | $129.36K 10-K · filed 2019-04-04 | |
| 2013-12-31 | $48.00K 10-K · filed 2014-03-31 | |
| 2012-12-31 | $36.00K 10-K · filed 2014-03-31 | -$36.00K 10-K · filed 2013-03-05 |
| 2011-12-31 | -$21.00K 10-K · filed 2013-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |